4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
10.07
-0.31 (-2.99%)
Jul 24, 2026, 4:00 PM EDT - Market closed
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 196 employees as of December 31, 2025. The number of employees decreased by 31 or -13.66% compared to the previous year.
Employees
196
Change (1Y)
-31
Growth (1Y)
-13.66%
Revenue / Employee
$450,214
Profits / Employee
-$820,903
Market Cap
526.42M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 196 | -31 | -13.66% |
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Jun 30, 2024 | 201 | 64 | 46.72% |
| Mar 31, 2024 | 171 | 34 | 24.82% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Sep 30, 2023 | 144 | 4 | 2.86% |
| Jun 30, 2023 | 137 | -1 | -0.72% |
| Mar 31, 2023 | 137 | 0 | - |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Sep 30, 2022 | 140 | 19 | 15.70% |
| Jun 30, 2022 | 138 | 34 | 32.69% |
| Mar 31, 2022 | 137 | 49 | 55.68% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Sep 30, 2021 | 121 | 43 | 55.13% |
| Jun 30, 2021 | 104 | 26 | 33.33% |
| Mar 31, 2021 | 88 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arvinas | 246 |
| ARS Pharmaceuticals | 159 |
| Prime Medicine | 146 |
| Silence Therapeutics | 88 |
| AgomAb Therapeutics NV | 62 |
| Tectonic Therapeutic | 60 |
| Altimmune | 57 |
| Contineum Therapeutics | 51 |
FDMT News
- 6 days ago - 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population - GlobeNewsWire
- 7 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 24 days ago - 4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewsWire
- 26 days ago - 4D Molecular completes enrollment in 4FRONT-2 trial - TheFly
- 26 days ago - 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital - GlobeNewsWire
- 26 days ago - 4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD - GlobeNewsWire
- 5 weeks ago - 4D Molecular Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - 4D Molecular Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts